Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Drug used in stem cell therapy may protect against smoke-induced lung injury

A drug used in stem cell therapy to treat certain cancers may also protect against cigarette smoke-induced lung injury.

5 Jul 2018

Streamlining and translating basic science discoveries into the clinic

To make sure that good ideas to enhance healthcare are not lost due to a lack of resources, a growing number of centers at Penn Medicine organize forums to pitch ideas to improve medical devices and technology, hold annual competitions to fund studies to improve patient care while keeping costs down, and sponsor seed grants for programs focused on patients who need individualized tailoring of their treatment.

2 Jul 2018

AbbVie and Calibr collaborate to develop T-cell therapies aimed at cancer

AbbVie , a research-based global biopharmaceutical company, and Calibr, a nonprofit drug discovery division of Scripps Research, today announced a collaboration to develop T-cell therapies aimed primarily at cancer, including solid tumors.

25 Jun 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018

Study tests accuracy of device designed to detect heart dysfunction in childhood cancer survivors

A wireless device designed for detection of heart dysfunction in childhood cancer survivors treated with anthracycline chemotherapy was accurate and displayed a low false-negative rate as compared to cardiac magnetic resonance imaging.

21 Jun 2018

Study: Oxidative stress can be used against tumors to treat cancer

Oxidative stress can help tumors thrive, but one way novel cancer treatments work is by pushing levels to the point where it instead helps them die, scientists report.

21 Jun 2018

Clinical trial targets metastatic colorectal cancer with new combination therapy

Rutgers Cancer Institute of New Jersey is offering a clinical trial targeting an advanced form of colorectal cancer with a combination vaccine/immunotherapy drug treatment.

19 Jun 2018

Drug used to treat myelofibrosis can awaken ‘dormant’ lymphomas in the bone marrow

Most patients with myelofibrosis, a rare chronic disorder of the haematopoietic cells of the bone marrow, benefit from drugs from the JAK2 inhibitor class: symptoms are relieved, survival extended and general quality-of-life enhanced.

18 Jun 2018

Some tumors use two levels of protection against immune system, shows study

In research published today, Babraham Institute researchers have shown that some tumors use not one but two levels of protection against the immune system.

8 Jun 2018

Study finds increase in lifestyle-related cancers over the past decade

Lifestyle-related cancers, such as lung, colorectal, and skin cancers, have increased globally over the past decade, according to the most comprehensive analysis of cancer-related health outcomes and patterns ever conducted.

4 Jun 2018

Phase I trial shows safety of investigational drug in treating chronic lymphocytic leukemia

Reporting results from a first-in-human phase I clinical trial, researchers at University of California San Diego School of Medicine have found that treatment with cirmtuzumab, an experimental monoclonal antibody-based drug, measurably inhibited the "stemness" of chronic leukemia cancer cells - their ability to self-renew and resist terminal differentiation and senescence.

1 Jun 2018

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Bristol-Myers Squibb Company today announced patient-reported outcomes data from the Phase 3 CheckMate -214 trial in intermediate- and poor-risk patients with advanced renal cell carcinoma treated with the Immuno-Oncology combination Opdivo plus low-dose Yervoy versus sunitinib over a two-year follow-up period.

1 Jun 2018

FDA approves first oral medication for adults with moderately to severely active ulcerative colitis

The U.S. Food and Drug Administration today expanded the approval of Xeljanz (tofacitinib) to include adults with moderately to severely active ulcerative colitis. Xeljanz is the first oral medication approved for chronic use in this indication.

30 May 2018

FDA-approved drug for lymphoma and leukemia may help treat common type of brain tumor

New Cleveland Clinic research shows for the first time that ibrutinib, an FDA-approved drug for lymphoma and leukemia, may also help treat the most common – and deadliest – type of brain tumor.

30 May 2018

Miniaturized device offers new way to gain insight into cell processes and communication

Like humans, cells of the same species each have a distinct "personality." When confronted with an external stimulus like a virus, they each secrete a different quantity of molecules and communicate with each other to a varying degree.

28 May 2018

Celgene to share new and updated data around novel hematological therapies

Celgene Corporation today announced that data from a broad range of early and late stage studies evaluating Celgene investigational agents and investigational uses of marketed products will be presented at the 23rd European Hematology Association annual meeting in Stockholm, Sweden, from June 14-17, 2018.

22 May 2018

Investigational drug offers hope of relief for celiac disease patients exposed to gluten

An investigational new drug offers hope of relief for celiac disease patients who are inadvertently exposed to gluten while on a gluten-free diet.

22 May 2018

Chemist begins new project to develop carbohydrate mimics to assist cancer therapies

Dr. Robert Britton firmly believes every molecule is important. This chemist doesn't want any molecule sitting unused on a laboratory shelf or in a fridge.

18 May 2018

New treatment regimen boosts survival for young adults and children with T-cell malignancies

In a federally funded, randomized phase III clinical trial performed by the Children's Oncology Group (COG), 90% of children and young adults with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LL) were alive four years after starting treatment regimens on this trial, and 84% were cancer free.

17 May 2018

Alexo Therapeutics marks next significant milestone by initiating ALX148 combination cohorts

Alexo Therapeutics, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced it has initiated ALX148 combination dosing with targeted antibody therapies in its Phase 1 clinical program in patients with advanced solid tumors and lymphoma.